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Genome-wide association studies have identified
GALNT2 as a candidate gene in lipid metabolism,
but it is not known how the encoded enzyme ppGal-
NAc-T2, which contributes to the initiation of mucin-
type O-linked glycosylation, mediates this effect. In
two probands with elevated plasma high-density
lipoprotein cholesterol and reduced triglycerides,
we identified a mutation in GALNT2. It is shown
that carriers have improved postprandial triglyc-
eride clearance, which is likely attributable to atten-
uated glycosylation of apolipoprotein (apo) C-III, as
observed in their plasma. This protein inhibits
lipoprotein lipase (LPL), which hydrolyses plasma
triglycerides. We show that an apoC-III-based
peptide is a substrate for ppGalNAc-T2 while its
glycosylation by the mutant enzyme is impaired. In
addition, neuraminidase treatment of apoC-III
which removes the sialic acids from its glycan
chain decreases its potential to inhibit LPL.
Combined, these data suggest that ppGalNAc-T2
can affect lipid metabolism through apoC-III glyco-Cell Msylation, thereby establishing GALNT2 as a lipid-
modifying gene.
INTRODUCTION
Genome-wide association studies (GWAS) have identified loci
that are associatedwith plasma lipids, but the unraveling of path-
ways through which these loci affect human metabolism is
awaited (Ku et al., 2010). This also holds true for GALNT2 (locus
NM_004481). In GWAS, SNPs in intron 1 of GALNT2 were found
to be associated with plasma high-density lipoprotein choles-
terol (HDL-c) and triglyceride levels (Kathiresan et al., 2008). It
was subsequently shown that hepatic overexpression and
silencing of GALNT2 in mice reduced and increased HDL-c
levels, respectively (Teslovich et al., 2010). It is, however, not
known through which mechanism the encoded enzyme UDP-
N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalacto-
saminyltransferase-2 (ppGalNAc-T2) mediates these effects.
The enzyme belongs to a family of ppGalNAc transferases
comprising 20 members in humans (Ten Hagen et al., 2003), all
catalyzing the transfer of GalNAc residues onto proteins, and
thereby initiating mucin-type O-glycan synthesis on threonine
and/or serine residues. The size of this enzyme family, its level
of evolutionary conservation, and the spatiotemporal changesetabolism 14, 811–818, December 7, 2011 ª2011 Elsevier Inc. 811
Table 1. Demographic, Lifestyle, and Lipid Characteristics of Carriers of the GALNT2D314A Mutation and Controls





Demographic and Lifestyle Characteristics
Age (year) 72.5 (15) 39.5 (21) 44.9 (13) 0.010 0.46
Gender (% male) 50 17 53 0.94b 0.12b
Body mass index (kg/m2) 20.9 (1.0) 25.5 (4.7) 24.4 (2.4) 0.063 0.49
Smoking, n (%) 0 1 (17) 5 (29) 0.37b 0.37b
Alcohol use (U/week)a 8 1 (0–9) 4 (0–15) 0.84 0.38
Diabetes mellitus type 2 (n) 0 1 1 - -
Hypertension (n) 0 0 0 - -
Cardiovascular events (n) 1 0 0 - -
Lipids and Lipoproteins
Total cholesterol (mg/dl) 278 (38) 241 (48) 195 (38) 0.010 0.026
LDL cholesterol (mg/dl) 158 (14) 156 (38) 128 (37) 0.27 0.12
HDL cholesterol (mg/dl) 106 (22) 63 (11) 56 (12) <0.001 0.21
Triglycerides (mg/dl)a 82.3 80 (59–100) 93 (72–114) 0.35 0.064
Apolipoproteins and LCAT Activity
ApoB (mg/dl) 105 (20) 121 (26) 110 (31) 0.82 0.45
Apo A-I (mg/dl) 220 (46) 147 (10) 135 (36) 0.007 0.44
Apo A-II (mg/dl) 23.6 (0.9) 29.3 (5.2) 29.4 (4.4) 0.08 0.96
ApoE (mg/dl) 2.2 (0.3) 2.3 (0.7) 3.19 (1.1) 0.23 0.09
Apo C-II (mg/dl) 3.8 (0.9) 4.2 (4) 4.05 (1.8) 0.85 0.89
Apo C-III (mg/dl) 9.6 (0.3) 10.1 (2.5) 10.3 (2.5) 0.72 0.89
LCATc activity (cholesteryl
ester/ml/hr)
17.3 (0.42) 17.7 (3.5) 16.9 (1.3) 0.73 0.26
Data are presented as mean (SD) unless otherwise specified.
a Alcohol use and triglycerides are given asmedian (interquartile range) and were log-transformed prior to statistical analysis. P values were calculated
using a t test unless indicated otherwise.
b For gender and smoking, a chi-square test was used.
c LCAT, lecithin cholesterol:acyltransferase.
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ppGalNAc-T2 Glycosylates Apolipoprotein C-IIIin expression patterns point to important and isoform-specific
functions for ppGalNAc-transferases in mammalian physiology
(Ten Hagen et al., 2003), but these are largely unknown to
date. Here, we provide evidence of a molecular pathway through
which ppGalNAc-T2 affects plasma lipids.
RESULTS
A Rare GALNT2 Variant
GALNT2 was sequenced in 243 subjects referred to our lipid
clinic for high plasma HDL-c levels (>95th percentile for age
and gender). We identified two unrelated heterozygotes for the
same point mutation at an evolutionary conserved position
(c.941A > C, p.D314A; see Table S1 available online). The muta-
tion was not found in 1,440 controls and 68 individuals with
HDL-c levels <5th percentile. In one family, 7 carriers and 14
unaffected family members were identified. In a second family,
1 carrier and 3 unaffected family members were found.
Clinical Examination, Lipids, Lipoproteins
Carriers underwent physical examination; blood tests including
protein spectrum, platelet aggregation, and plasma coagulation
assays; and ultrasonography for carotid intima media thickness
measurements. These investigations did not reveal any abnor-812 Cell Metabolism 14, 811–818, December 7, 2011 ª2011 Elseviermalities. Measurements in fasting plasma showed that the
probands have high HDL-c and low triglycerides (Table 1).
Compared to 17 family controls, the 6 additional affected family
members presented with a significant increase in total plasma
cholesterol levels (p = 0.026) associated with nonsignificant
increases in HDL-c and low-density lipoprotein cholesterol while
a trend toward decreased triglyceride levels was observed
(p = 0.064). See Table S2 for individual lipid profiles of all study
subjects.
Identification of ppGalNAc-T2 Substrates
Plasma proteins were analyzed with 2D gel electrophoresis
(2DE) to identify potential substrates of ppGalNAc-T2. Head-
to-head comparisons of pairs of carriers and age-and-gender-
matched family controls revealed differences in the relative
distribution of apoC-III isoforms (Figure 1A). Compared to
controls, carriers had 6.6-fold increased levels of nonsialylated
apoC-III0 (p = 0.01) and decreased levels of monosialylated
apoC-III (apoC-III1; p = 0.05), while levels of disialyated apoC-III
(apoC-III2) were similar. MALDI-TOF mass spectrometry
confirmed that the aberrant proteins were the denoted apoC-III
isoforms (Table S3). Figure 1B illustrates increased levels of
apoC-III0 isoforms in a carrier, while apoC-III of a noncarrier is
only present as apoC-III1 or apoC-III2.Inc.
Figure 1. 2DE Analysis of ApoC-III Isoforms in Carriers of the GALNT2D314A Mutation Compared to Noncarriers and Enzyme Kinetics of Wild-
Type and Mutant ppGalNAc-T2
(A) Compared to controls, carriers have 6.6-fold increased levels of nonsialylated apoC-III0 (p = 0.01) and decreased levels of monosialylated apoC-III (apoC-III1;
p = 0.05), while levels of disialyated apoC-III (apoC-III2) are similar. Data are expressed as means. Error bars are SEMs. P values are for Mann-Whitney U tests.
(B) Western blot of 2DE gel showing a carrier with increased levels of apoC-III0 isoforms, while apoC-III of a family control is only present as apoC-III1 or apoC-III2.
Note that apoC-III0 comprises nonsialylated apoC-III (apoC-III-GalNAc and apoC-III-GalNAc-Gal) and apoC-III that is not glycosylated (Bruneel et al., 2007).
(C andD) Enzymeswere overexpressed in COS7 cells. y axis indicates rate of transfer as dpm/hr/densitometric unit of enzyme. Figures represent kinetic plots and
averages of replicate peptide glycosylation experiments catalyzed by wild-type or mutant ppGalNAc-T2. Mixtures of purified recombinant proteins with various
concentrations of EA2 (C) or apoC-III (D) peptide substrates were used, and kinetic plots were fit to Michaelis-Menten equation. Kinetic parameters for peptide
glycosylation by both enzymes are given in tables as means. Error bars are SD. N, number of replicate experiments.
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ppGalNAc-T2 Glycosylates Apolipoprotein C-IIIFunctional Characterization of ppGalNAc-T2D314A
To study whether the mutation was associated with changes at
the mRNA and/or protein levels, we used skin fibroblast cultures
from three carriers of the mutation and three unrelated controls.
Figure S1 shows that GALNT2 mRNA and protein levels in
lysates of these cells were similar in both groups (Figures S1A
and S1B, respectively).
To study the effects of the mutation on enzyme function,
mutant and wild-type ppGalNAc-T2 were expressed in COS7
cells. A study of enzyme kinetics showed that the maximum
number of enzymatic reactions catalyzed per second (Kcat) by
mutant ppGalNAc-T2 was more than 2-fold lower compared to
wild-type ppGalNAc-T2 when using a standard ppGalNAc-T
substrate (EA2) (p < 0.05, Figure 1C) (Ten Hagen et al., 2003).
Since we found attenuated glycosylation of apoC-III in carriers,
we also tested an 11-mer apoC-III peptide harboring the Thr74Cell Mresidue which is normally glycosylated in native apoC-III (Vaith
et al., 1978) as substrate. Figure 1D shows that for this peptide
there was also a more than 2-fold lower Kcat (p < 0.01). The
reductions in Kcat were observed without significant reductions
in Km.
ppGalNAc-T1, the only other ppGalNAc-T reported to be
highly expressed in human liver (Ten Hagen et al., 2003) and
an enzyme with broad substrate specificity, had a high activity
toward the EA2 substrate (Figure S1C) compared to wild-type
ppGalNAc-T2 but was unable to use the apoC-III peptide as
substrate (Figure S1D).
Oral Fat Challenge
Since apoC-III is an inhibitor of LPL (Jong et al., 1999), the sole
enzyme responsible for plasma triglyceride hydrolysis, we
challenged carriers and noncarriers with an oral fat load. Aetabolism 14, 811–818, December 7, 2011 ª2011 Elsevier Inc. 813
Figure 2. Carriers of the GALNT2D314A Mutation Have Improved Postprandial Plasma Triglyceride Clearance
Depicted are plasma triglyceride levels before (t = 0) and after an oral fat challenge (t = 1–6 hr) in four carriers and four noncarriers. Compared to noncarriers (open
symbols), carriers (closed symbols) have lower baseline triglyceride levels, earlier maximum triglyceride levels (t = 3 versus t = 4 in controls), and a reduced overall
triglyceride increase. The estimated difference in plasma triglycerides (averaged over time) between carriers and noncarriers using a mixed linear model was
15.4 mg/dl (95% confidence interval 3.3–27.5; p = 0.014). Data are expressed as means. Error bars are SEM. The inset shows that the oral fat challenge did not
change plasma LPL levels in carriers and controls when using a commercially available ELISA. The LPL levels appear lower in carriers compared to controls, but
these were not significantly different from controls at any time point as assessed by unpaired Student’s t tests. Data are given as means. Error bars are SD.
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ppGalNAc-T2 Glycosylates Apolipoprotein C-IIIsignificantly improved postprandial plasma triglyceride clear-
ance was observed in four carriers compared to four noncarriers
(p = 0.014; Figure 2). In addition, triglyceride levels peaked at 3 hr
in carriers instead of 4 hr in noncarriers. The inset of Figure 2
shows that the lipid load did not affect the levels of plasma
LPL in both groups at each time point.
To investigate apoC-III distribution over lipoproteins, we frac-
tionated plasma using fast protein liquid chromatography (FPLC)
followed by apoC-III immunoblotting (Figure S2) and measured
total apoC-III at t = 0 and t = 4 in all individuals. Average total
apoC-III levels were not different between carriers and controls
at these two time points. The top two panels of Figure S2
show that the distribution of apoC-III over lipoproteins was
similar in carriers and noncarriers at baseline. Four hours post-
prandial, however, apoC-III was significantly increased in the
HDL fraction in carriers compared to controls (p = 0.029). In addi-
tion, we used plasma to generate FPLC cholesterol profiles and
triglyceride profiles (Figure S2, lower panels), but we did not
identify significant quantitative differences between carriers
and controls when comparing these profiles at t = 0 or at t = 4 hr.
Inhibition of Lipoprotein Lipase
Having established that apoC-III is a specific substrate for
ppGalNAc-T2, we studied whether sialylation of the sole
O-linked glycan of apoC-III affects this property. To this end,
we treated purified human apoC-III that was isolated from very
low density lipoprotein (VLDL) of healthy controls (obtained
from a commercial source) with neuraminidase. Figure 3A shows
that neuraminidase treatment resulted in a shift from the acidic814 Cell Metabolism 14, 811–818, December 7, 2011 ª2011 ElsevierapoC-III isoforms to apoC-III0 due to the loss of sialic acids.
This resulted in a significant reduction of the potential of apoC-
III to inhibit human recombinant LPL activity. While untreated
apoC-III inhibited LPL by 54%, neuraminidase-treated apoC-III
inhibited LPL by 26% (p < 0.001; see Figure 3B).DISCUSSION
This study identifies a missense mutation in GALNT2 causing
a reduction of ppGalNAc-T2 catalytic activity which in carriers
of the mutation is associated with improved postprandial triglyc-
eride clearance. The data suggest that this enzyme mediates
these effects through glycosylation of apoC-III, an established
inhibitor of LPL. The decrease of ppGalNAc-T2 activity and
increase in HDL-c in the probands of this study is in line with
the finding that GALNT2 silencing increases HDL-c in mice
(Teslovich et al., 2010).
The p.D314A mutation in ppGalNAc-T2 causes a reduction of
glycosylation activity when using either a general ppGalNAc-T
substrate or an apoC-III-based peptide. We also show that
ppGalNAc-T2, but not ppGalNac-T1, can use the apoC-III
peptide as substrate. Since ppGalNAc-T1 is the only other
ppGalNAc-T expressed in human liver (Ten Hagen et al., 2003),
this result indicates that apoC-III is preferentially glycosylated
by ppGalNAc-T2, an intriguing finding, given the broad substrate
specificity of ppGalNAc-T1. Molecular modeling studies suggest
that the observed loss of catalytic activity may be due to a loss of
enzyme stability (Figure S3 and Movie S1).Inc.
Figure 3. Inhibition of Lipoprotein Lipase-Mediated Triglyceride
Hydrolysis
(A) 2DE analysis of untreated purified human apoC-III that was isolated from
plasma VLDL (Academy Bio-Medical Company). In addition to the common
apoC-III2 and apoC-III1 isoforms, apoC-III in VLDL is also present in a more
acidic isoform (denoted apoC-III3), as has beendescribed previously (Wopereis
et al., 2003; Jabs and Assmann, 1987). The second panel shows that treatment
of this apoC-III with neuraminidase results in desialylation of apoC-III, as
evidenced by the appearance of the nonsialylated isoform, apoC-III0.
(B) Desialylation of this apoC-III with neuraminidase attenuates its potential to
inhibit recombinant human LPL. LPL activity is inhibited by 54% after
incubation with untreated apoC-III. Desialylation with neuraminidase reduces
the inhibitory capacity of apoC-III (p < 0.001). Vertically shaded bar indicates
that catalytic activity of LPL is not affected by neuraminidase treatment.
Experiments were conducted in triplicate. Data are expressed as means. Error
bars are SD.
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ppGalNAc-T2 Glycosylates Apolipoprotein C-IIIppGalNAc-Ts catalyze coupling of GalNAc to Thr or Ser resi-
dues of protein substrates. Subsequently, the O-glycan chain
may be elongated with a b1,3-linked galactose and negatively
charged sialic acids to formmucin-core 1 structures (Ten Hagen
et al., 2003). Failure of GalNAc addition can thus result in altered
charge and/or mass of target proteins. 2DE and subsequent
immunoblotting of plasma samples led to the discovery of
marked changes in apoC-III isoforms in the carriers. This protein
could indeed be a substrate for ppGalNAc-T2, since it has
a single O-glycan chain at Thr74 (Vaith et al., 1978) that is
preceded by Pro73 and Val71 (Gerken et al., 2011). In normal
plasma, three main apoC-III isoforms are usually discriminated:
apoC-III0, apoC-III1, and apoC-III2, with zero, one, or two sialic
acid residues, respectively. Compared to apoC-III2 and apoC-
III1, apoC-III0 is only present at very low levels (Wopereis et al.,
2003). Comparing carriers and controls, we identified a marked
6.6-fold increased concentration of nonsialylated apoC-III0 and
a 32% decrease of monosialylated apoC-III1. The absence of
a change in apoC-III2 concentration when comparing carriers
and controls is intriguing, especially when considering that our
in vitro analyses show that the ppGalNAc-T1 enzyme cannot
use the apoC-III peptide as substrate. However, we study
a reduction in the initial step of the apoC-III glycosylation, which
would lead to less apoC-III molecules available for sialylation.
Besides rendering more unglycosylated apoC-III (apoC-III0),
this could increase the probability of disialylation (rendering
apoC-III2) rather than monosialylation (rendering apoC-III1) of
the remaining apoC-III molecules, which would explain the distri-
bution pattern observed in the heterozygotes.Cell MApoC-III is an inhibitor of LPL-mediated hydrolysis of plasma
triglycerides in VLDL and chylomicrons (Jong et al., 1999),
thereby affecting both HDL-c and triglyceride levels. On the
other hand, apoC-III is used as a model molecule to study
congenital disorders of mucin O-linked glycosylation (Wopereis
et al., 2003). Combined, these findings suggest that altered
glycosylation of apoC-III due to attenuated ppGalNAc-T2 activity
causes an increased capacity to clear plasma triglycerides in
carriers of the mutation. To test this, we challenged carriers
and noncarriers with an oral fat load and observed a significantly
improved postprandial plasma triglyceride clearance. The
molecular details of this process are very difficult to unravel,
due the complexity of in vivo plasma triglyceride lipolysis (Rip
et al., 2006). From what is currently known, this process involves
multiple interactions of apoC-II as cofactor of LPL (Jong et al.,
1999), apoA-V as modulator of LPL function (van Dijk et al.,
2004), and angiopoietin-related proteins 3 and 4 (Li, 2006) as
LPL inhibitors. While most of these factors are present on HDL,
VLDL, and chylomicrons, the apolipoproteins rapidly exchange
between these lipoproteins (Eisenberg et al., 1972). In addition,
the cocktail of activation and inhibitory processes at specific
and differentially regulated sites of action (adipose tissue, skel-
etal muscle, heart muscle) (Zechner, 1997) occur with simulta-
neous effects on the hepatic uptake of VLDL and chylomicron
remnants, which also reduces plasma triglyceride levels (LPL
and apoC-III can, e.g., also act as ligands for hepatic receptors)
(Beisiegel et al., 1991).
With this complexity in mind, we have used two straightfor-
ward approaches to try unraveling the molecular mechanism
that may explain our findings. In one experiment, it is shown
that under fasting conditions, plasma concentrations of apoC-III
and its distribution over lipoproteins are similar in carriers and
controls. At 4 hr after the oral fat load, however, total apoC-III
levels remained similar in carriers and controls, but apoC-III
was significantly increased in the HDL fraction of only carriers.
Since lipolysis occurs at the surface of VLDL and chylomicrons,
a change of apoC-III distribution over lipoproteins can be
expected to affect plasma triglyceride hydrolysis. In a second
experiment, we explored whether the glycan chain of apoC-III
affects LPL activity. Using neuraminidase, we showed that
desialylation of apoC-III indeed affects its potential to inhibit
LPL. These data combined suggest that attenuated ppGalNac-
T2-mediated glycosylation of apoC-III is involved in mediating
the observed effects on plasma lipids. ApoC-III has, to our
knowledge, not been studied in the context of attenuated
ppGalNAc-T2 activity, but there are several aspects that merit
careful discussion.
It has been reported that the N terminus of apoC-III is respon-
sible for inhibiting LPL while its glycan chain is located in the
C-terminal domain, and that synthetic apoC-III lacking the
carbohydrate moiety can still inhibit LPL (McConathy et al.,
1992). These and other investigators (Roghani and Zannis,
1988) have, however, not addressed the potential of the different
apoC-III isoforms to inhibit LPL activity. Also, the effect of a loss
of the carbohydrate moiety as a result of loss of ppGalNAc-T2
activity has not been studied in vivo. In addition, we also show
that carriers have an altered distribution of apoC-III over lipopro-
teins in the postprandial phase. The notion that negative charge
of apoC-III has effects on the distribution of apoC-III overetabolism 14, 811–818, December 7, 2011 ª2011 Elsevier Inc. 815
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1994), and it is likely that this effect also mediates part of the lipid
changes that we observe.
Second, others have described a family with high apoC-III0
(Maeda et al., 1981) due to heterozygosity for an APOC3 muta-
tion that changes the Thr74 to an alanine (Maeda et al., 1987).
Thus, theoretically, half of the apoC-III in these individuals is
not glycosylated. Although these investigators did not find
marked effects on lipid levels, two out of three carriers had
reduced triglyceride levels. This study of Maeda and the current
study combined suggest that mutations in apoC-III as well as
ppGalNAc-T2 can translate into similar fasting plasma lipid
profiles. The current postprandial lipid data are moreover
remarkably similar to those reported by Pollin, who studied the
effects of an APOC3 non-sense mutation on postprandial lipid
levels (Pollin et al., 2008).
Third, apoC-III isoforms have been extensively studied in man
with various outcomes. Supporting our hypothesis, it has been
shown that of the three apoC-III isoforms, the nonsialyated
apoC-III0 is least associated with plasma triglyceride levels
(Mauger et al., 2006). Others (Stocks et al., 1979) furthermore
reported that neuraminidase treatment of hypersialylated
apoC-III from VLDL of hypertriglyceridemic patients reduces its
capacity to inhibit LPL. In addition, Kashyap showed decreased
levels of the apoC-III0 isoform in 10 subjects with severely
increased triglyceride levels (Kashyap et al., 1981). By contrast,
van Barlingen showed an increase of apoC-III0 in 12 patients with
severe familial hypertriglyceridemia (van Barlingen et al., 1996).
The latter contrasting data show that apoC-III0 levels are not
predictive of triglyceride levels, especially not in patients with
hypertriglyceridemia of different molecular etiology. Many other
parameters may affect apoC-III sialylation levels in plasma, such
as the levels of sialyltransferase, sialidase activity, and the
number of asialoglycoprotein receptors (Maeda et al., 1981),
which may differ under pathophysiological conditions in patients
and beneficial conditions observed in our study subjects.
Fourth, we did not study putative effects of theGALNT2muta-
tion on the hepatic uptake of lipoproteins (Shelburne et al., 1980;
Windler et al., 1980), but Windler and Havel showed that neither
the human apoC-III1 and apoCIII2 isoforms (Windler and Havel,
1985) nor the rat apoC-III0 and apoC-III3 isoforms (Windler
et al., 1980) are different in this regard.
Finally, it has recently been reported that ppGalNAc-T2-medi-
ated glycosylation of angiopoietin-related protein 3 affects
proteolytic processing of the protein which is required to render
angiopoietin-related protein 3 an active inhibitor of LPL (Schjold-
ager et al., 2010). Reduced ppGalNAc-T2 activity would cause
improved processing of angiopoietin-related protein 3, thereby
increasing LPL inhibition, whichwould result in increased plasma
triglyceride and decreased HDL-c levels. However, the effects of
the loss-of-function mutation described here, as well as the
silencing studies of GALNT2 in mice (Teslovich et al., 2010),
show the opposite. Figures S4A and S4B, moreover, show iden-
tical plasma concentrations of processed and unprocessed
angiopoietin-related protein 3 in plasma of carriers and noncar-
riers, suggesting that in our study there is no direct evidence that
changes in angiopoietin-related protein 3 cause the lipid pheno-
type that we observe. However, it is possible that ppGalNac-T2
affects lipid metabolism through other mucin-type O-linked816 Cell Metabolism 14, 811–818, December 7, 2011 ª2011 Elsevierglycosylated proteins. In this regard, studying apoA-II and
apoE did not reveal differences in total plasma concentration
(see Table 1) and isoforms (Figures S4C and S4D), while plasma
activity of lecithin:cholesterol acyltransferase did not differ
between carriers and controls (Table 1).
In conclusion, this study suggests that ppGalNAc-T2 can
affect plasma lipids through posttranslational modification of
apoC-III. This finding connects the glycosylation and cardiovas-
cular research fields by showing how a mucin-type O-linked
glycosylation defect can cause changes in lipid metabolism.
As of yet, lipid metabolism in heterozygotes for congenital disor-
ders of glycosylation has to our knowledge not been studied,
which offers opportunities for future research, likely resulting in
further insight in the relevance of glycosylation in lipid metab-
olism. Finally, this study also underscores the relevance of
GWAS for the identification and unraveling of pathways in
complex disorders.
EXPERIMENTAL PROCEDURES
Participants, DNA Analysis, Lipids
The participants with high and lowHDL-cwere recruited at the outpatient clinic
in Amsterdam or at the community hospital in Hilversum, The Netherlands.
Controls (n = 1440) were recruited at the collection sites of the Sanquin Blood
Bank. Oral fat challenges were carried out as described (Nierman et al., 2005).
The local institutional review board approved of all studies described and all
participants gave written informed consent.
The GALNT2 mutation was identified through massive parallel sequencing
(Herman et al., 2009) and was confirmed by Sanger sequencing. Genotyping
of controls was performed on a LightCycler (Roche 480). Total cholesterol,
LDL-c, HDL-c, triglycerides, and apoA-I, apoE, apoC-II, and apoC-III were
measured on a COBAS MIRA analyzer using commercially available assays
(Randox, Wako). FPLC to separate lipoproteins was carried out as described
(Levels et al., 2003). Fractions were collected for apoC-III immunoblotting.
Plasma LPL was measured using a commercial ELISA (Dainippon).
2D Gel Electrophoresis and Mass Spectrometry
2DE of plasma proteins was performed using IPGphor and Multiphor (Amer-
sham Biosciences). Aliquots (200 mg) for western blots were applied on pH
4-7 IPGs and plasma (300 mg) for preparative gels on pH 3-10 IPGs (Karlsson
et al., 2005). Separated proteins for quantification and identification were
detected by silver staining (Shevchenko and Shevchenko, 2001). For protein
identification, tryptic digests of proteins excised from the gels were analyzed
by mass spectrometry (see the Supplemental Information for more detail).
For western blots, proteins were transferred to a PVDFmembrane. After block-
ing and incubation with primary antibodies against candidate proteins, the
membranes were incubated with HRP-conjugated secondary antibodies.
Proteins were visualized using an ECL plus western blotting detection system,
exposed to X-ray film, and developed. Isoform intensities were determined as
optical density per mm2 and expressed as percentage of the total protein level
for each protein.
In Vitro Analyses
Generation of pIMFK4 constructs for wild-type human T1, wild-type T2, and
mutant T2 is described in the Supplemental Information. COS7 cells
were grown to 90% confluence and transfected with each of the vectors.
Enzyme activities were measured against EA2 and an apoC-III peptide
(PEVRPTSAVAA) using radioactively labeled UDP-GalNAc (Hagen et al.,
1997). Wild-type and mutant T2 activities were measured as described
(O’Connell and Tabak, 1993). Kinetic parameters were calculated using Hanes
plot. To calculate kcat, enzyme concentrations were measured by western
blots using a standard curve made with known concentrations of FLAG-BAP
(Sigma-Aldrich).
ApoC-III isolated from human VLDL (Academy Bio-Medical Company) was
treated with neuraminidase (NorthStar). A [3H]triolein substrate (Nilsson-EhleInc.
Cell Metabolism
ppGalNAc-T2 Glycosylates Apolipoprotein C-IIIand Schotz, 1976) was used to measure the potential of apoC-III to inhibit
recombinant human LPL.
Statistical Analyses
Parameters were compared between carriers and noncarriers using Student’s
t tests or Mann-Whitney U tests, where appropriate, for continuous variables.
Chi-square tests were used for categorical variables. Fat challenge data were
analyzed in a mixed linear model. Statistical analyses were performed using
SPSS software (version 16.0, SPSS Inc., Chicago, IL). Error bars indicate stan-
dard deviation unless otherwise indicated. Probability values of <0.05 were
considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, one movie,
Supplemental Experimental Procedures, and Supplemental References and
can be found with this article online at doi:10.1016/j.cmet.2011.11.005.
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